We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Higher generic drug use by one of the country’s largest pharmaceutical benefit managers (PBMs) last year slowed the cost per prescription rate to a 7.9 percent increase, compared to the 13.1 percent rate increase over the previous two years.
Sandoz plans to acquire Canadian generic firm Sabex Holdings for $565 million in a deal that gives Sandoz access to new markets and production capabilities in generic injectables.